Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Cemiplimab-RWLC in Non-small cell lung cancer stage I: NCT07808138 Clinical Landscape Report 2026
11 September 2026
NCT07808138 clinical landscape for Non-small cell lung cancer stage I: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Resmetirom in Metabolic Dysfunction Associated Steatohepatitis: NCT07680478 Clinical Landscape Report 2026
11 September 2026
NCT07680478 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Ipilimumab in Mesothelioma, Malignant: ACTRN12626000505303 Clinical Landscape Report 2026
11 September 2026
ACTRN12626000505303 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tunlametinib in NRAS Mutant Melanoma: NCT07750067 Clinical Landscape Report 2026
11 September 2026
NCT07750067 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SR-604 in Hemophilia B: NCT07644832 Clinical Landscape Report 2026
11 September 2026
NCT07644832 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Hepatocellular Carcinoma: NCT07790419 Clinical Landscape Report 2026
11 September 2026
NCT07790419 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab in Idiopathic Pulmonary Fibrosis: NCT07674745 Clinical Landscape Report 2026
11 September 2026
NCT07674745 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JBI-778 in Glioblastoma: NCT07751744 Clinical Landscape Report 2026
11 September 2026
NCT07751744 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LTX-002 in Amyotrophic Lateral Sclerosis: NCT07660614 Clinical Landscape Report 2026
11 September 2026
NCT07660614 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in BRAF V600E mutant Colorectal Cancer: NCT07809893 Clinical Landscape Report 2026
11 September 2026
NCT07809893 clinical landscape for BRAF V600E mutant Colorectal Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma: NCT07814287 Clinical Landscape Report 2026
11 September 2026
NCT07814287 clinical landscape for Locally Advanced Head and Neck Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
FMC-220 in Ovarian Cancer: NCT07752875 Clinical Landscape Report 2026
11 September 2026
NCT07752875 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.